Investor Relations
Medgen Life Science is positioned at the intersection of China’s growing demand for regenerative repair materials and the national push for import substitution in medical devices.
Market Opportunity
Multiple converging trends are creating substantial growth opportunities in China’s regenerative repair materials market.
96.9B RMB
China’s bone repair materials market is projected to reach 96.9 billion RMB, growing at 19.8% CAGR. Driven by aging population, increasing orthopedic conditions, and rising surgical volumes.
19.8%
CAGR growth rate. Government-led volume-based procurement reforms have made implant procedures more accessible. Bone grafting is required in a significant proportion of implant cases.
Import Substitution
National policies strongly encourage adoption of domestically developed medical devices. Medgen’s NMPA-approved products provide comparable quality at competitive pricing.
Funding History
Medgen has secured institutional financing to fund product development, regulatory approvals, and commercial launch activities. A+ round total nearing 100 million RMB.
Tens of Millions RMB
Raised to accelerate regulatory submissions for BoneSwift™ and PoroGraft®, expand the team, and build commercial infrastructure for product launches.
Read announcement →Led by Yuansheng Ventures
Follow-on round strengthening the balance sheet ahead of dual product approvals, supporting nationwide commercial rollout and international market development.
Read announcement →Product Pipeline
A diversified portfolio of regenerative repair products spanning approved products and development-stage candidates.
BoneSwift™
ApprovedInjectable Bone Repair Material
China’s first pre-filled injectable bone repair material. NMPA Class III approved. 2 indications (limb + spinal), Vietnam Class D approved.
PoroGraft®
ApprovedXenograft Bone Graft
China’s first porcine-derived oral bone graft material. NMPA Class III approved. Vietnam Class D approved.
PRP System
ApprovedPlatelet-Rich Plasma
NMPA Class III approved PRP preparation system. Three-chamber integrated design with proprietary centrifugation. Approved in China, Vietnam, and Indonesia.
Next-Generation Biomaterials
ResearchFuture Pipeline
Shoulder cuff patch (Shenzhen major tech project), HA microsphere gel injectable (in clinical), biomedical collagen, and ECM products in development.
Competitive Advantages
Medgen’s competitive position is underpinned by a combination of technology differentiation, regulatory milestones, and market timing.
BoneSwift™ is the first pre-filled injectable bone repair material approved in China, establishing a new product category with significant barriers to entry.
Proprietary processing of natural bone tissue preserves native collagen and mineral structure, delivering superior osteoconductive performance vs synthetic alternatives.
Built on a strong academic foundation with 40+ intellectual property rights, including national utility model patents.
Three NMPA Class III medical device approvals (BoneSwift™, PoroGraft®, PRP System), demonstrating strong regulatory execution.
Government policies actively encourage domestic medical device adoption. Medgen’s products offer comparable or superior performance to imported alternatives.
Core technology platforms are extensible across multiple product categories. Pipeline includes shoulder cuff patch, HA microspheres, collagen, and ECM products.
Recent Milestones
All News →Medgen Life Science's BoneSwift™ receives NMPA Class III certification as China's first hydroxyapatite pre-filled bone repair material, offering ready-to-use convenience and enhanced surgical efficiency.
Medgen Life Science's independently developed PoroGraft® oral bone graft material has officially launched — the first domestically produced porcine-derived xenograft bone graft in China, offering a new treatment experience for oral restoration.
Medgen's independently developed BoneSwift™ pre-filled injectable bone filling material receives Class D medical device registration from Vietnam's Ministry of Health, the highest risk classification in Vietnam's regulatory system.
Medgen Life Science has been officially designated as a Shenzhen "Specialized, Refined, Differentiated, and Novel" (SRDN) small and medium enterprise in recognition of its sustained technological innovation.
Medgen's PoroGraft® oral bone filling material receives Class D medical device registration in Vietnam — the highest risk classification — becoming the company's third product approved in Vietnam and marking the systematic deployment of a multi-product portfolio in Southeast Asia.
Investor Inquiries
For investor relations inquiries, partnership discussions, or to request additional information about Medgen Life Science, please contact us.
info@medgenlife.com
Contact Us